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CASE REPORTTracheal squamous cell carcinoma (SCC) metastatic to
the skin in a patient on a checkpoint inhibitor
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racheal squamous cell carcinoma (SCC) is an
extremely rare cancer, with an incidence of
fewer than 10 cases diagnosed in the United
States annually.1 To our knowledge and after exten-
sive literature searching in MEDLINE (PubMed) and
Embase databases for published English-language
articles, this is the first report of tracheal SCC
metastatic to the skin. Our patient was participating
in an antibody-blocking interaction with program-
med death ligand 1 (anti-PD-L1) checkpoint inhibitor
trial, which may or may not have contributed to his
metastatic disease.Fig 1. Metastatic tracheal squamous cell carcinoma initial
presentation.CASE REPORT
A 34-year-old man with a known history of
tracheal SCC metastatic to bone was enrolled on an
institutional review boardeapproved clinical trial
using a checkpoint inhibitor (immunotherapy). He
presented with a new and enlarging lesion on the
right alar crease for 6 months (Fig 1). Physical
examination revealed a 3-mm dome-shaped pink
papule with telangiectases, which was removed with
shave biopsy. Histopathology showed an essentially
normal epidermis with dermal proliferation of
epithelioid cells in islands (Fig 2, A). The cells were
remarkable for marked pleomorphism, hyperchro-
matic nuclei, numerous atypical mitoses, crowding
of nuclei, and displacement of normal cutaneous
structures. Examination of the pathology demon-
strated a robust lymphocytic infiltration (immune
reactivity to the malignancy) and vascular dilatation,the Departments of Dermatologya and Hematology-
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ent of Defense.which is suggestive of neovascularization. The spec-
imen stained positively for cytokeratin 5/6 and 7 (Fig
2, B), and stained negatively for cytokeratin 20 and
thyroid transcription factor 1. These histopatholog-
ical and immunohistochemical findings were consis-
tent with metastatic SCC. He had since developed a
recurrence at the original site of biopsy, and new
similar-appearing lesions on his fingers, which had
all responded to radiotherapy (Fig 3). The patient
remained on immunotherapy, which was an infu-
sional anti-PD-L1, and had stable disease in all of his
sites for 8 months. The patient had stable disease in
all of his sites for 8 months. After this time, his tumorCorrespondence to: Nicole M. Cassler, MD, Department of
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Fig 2. A, Histopathology of metastatic squamous cell carcinoma, right nasal ala. (Hematoxylin-
eosin stain; original magnification: 310.) B, Cytokeratin 7 stain, highlighting neoplastic cells.
(Original magnification: 320.)
Fig 3. Multiple foci of suspected metastatic squamous cell
carcinoma.
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Cassler, Marquart, and Carter 309progressed in all of his known cutaneous sites. Over
a period of 2 years, his disease burden increased until
he succumbed to his disease.
DISCUSSION
Advanced tracheal SCC commonlymetastasizes to
viscera,2 which was our patient’s primary known
sites of disease before enrolling on the trial. While on
the trial with anti-PD-L1 therapy these sites remained
stable, which was documented using contrast
computed tomography scans for 8 months. During
his treatment, multiple small nontargetable lesions
developed within the dermis. The most common
side effects currently associated with anti-PD-L1
antibody therapy include fatigue, asthenia, nausea,
diarrhea, and rash. Specific cutaneous side effects
known to be associated with immunotherapeutics
include rash, pruritus, hyperpigmentation, and
Sweet syndrome.3,4 Our patient’s cancer progressed
while receiving immune checkpoint inhibition inboth cutaneous and subcutaneous areas. We are left
to postulate that this is either a dynamic of the
biology of our patient’s tumor, or that it may be in an
area where the immune system has a lower recog-
nition of malignant cells secondary to constant
exposure to the outside environment. The immune
system’s inhibitory membrane (checkpoint) ligands
have been found to be increased in known immu-
nogenic tumors including nonsmall cell lung cancer,
melanoma, and renal cell cancer.5 Our patient
participated in a phase-I, dose-escalation portion of
the study, whichmay also lead to the assumption that
not all of his checkpoint inhibitory ligands were
inhibited. The patient participated in dose level 2 of 6
dose levels. This is the first reported case to our
knowledge of tracheal SCC metastatic to the skin in a
patient receiving a checkpoint inhibitor. Although it
is too early to draw a conclusion, this may become
either a common area to which cutaneous metastasis
break through or an unusual correlation.
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